CN112996562A - 治疗阿尔茨海默病的方法 - Google Patents
治疗阿尔茨海默病的方法 Download PDFInfo
- Publication number
- CN112996562A CN112996562A CN201980071651.0A CN201980071651A CN112996562A CN 112996562 A CN112996562 A CN 112996562A CN 201980071651 A CN201980071651 A CN 201980071651A CN 112996562 A CN112996562 A CN 112996562A
- Authority
- CN
- China
- Prior art keywords
- hydroxypropyl
- beta
- cyclodextrin
- cyclodextrin composition
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752131P | 2018-10-29 | 2018-10-29 | |
| US62/752,131 | 2018-10-29 | ||
| US201962885053P | 2019-08-09 | 2019-08-09 | |
| US62/885,053 | 2019-08-09 | ||
| PCT/US2019/057784 WO2020092107A1 (en) | 2018-10-29 | 2019-10-24 | Methods for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112996562A true CN112996562A (zh) | 2021-06-18 |
Family
ID=68583503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980071651.0A Pending CN112996562A (zh) | 2018-10-29 | 2019-10-24 | 治疗阿尔茨海默病的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11925659B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873604B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7446322B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210084480A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112996562A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008139A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114021C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2992137T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3873604T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092107A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025214478A1 (zh) * | 2024-04-12 | 2025-10-16 | 北京华昊中天生物医药股份有限公司 | 一种优替德隆药物组合物及其制备方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| AU2020204925B2 (en) | 2019-01-03 | 2025-11-20 | Cyclarity Therapeutics, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| AU2021284155A1 (en) * | 2020-06-02 | 2023-01-05 | National University Of Singapore | Compositions, their uses in therapy and methods thereof |
| WO2022051631A1 (en) | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| CA3200988A1 (en) * | 2020-11-06 | 2022-05-12 | John Jahangir Alam | Treatment of gait dysfunction in neurodegenerative disease |
| WO2022099094A1 (en) * | 2020-11-06 | 2022-05-12 | Eip Pharma, Inc. | Compositions and methods for treating depression |
| WO2022197640A1 (en) * | 2021-03-14 | 2022-09-22 | Massachusetts Institute Of Technology | Apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells |
| EP4433828A1 (en) * | 2021-11-18 | 2024-09-25 | Vib Vzw | Improved gamma-secretase inhibitor screening assays |
| JP2025506676A (ja) | 2022-02-18 | 2025-03-13 | ベレン セラピューティクス ピー.ビー.シー. | ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法 |
| WO2023191425A1 (ko) * | 2022-03-28 | 2023-10-05 | 주식회사 비엔에이치리서치 | 약물의 전기생리학적 스크리닝 방법 |
| CN114569742B (zh) * | 2022-05-09 | 2022-07-19 | 北京剂泰医药科技有限公司 | 一种组合物及其制备方法和应用 |
| KR20250024808A (ko) * | 2022-06-13 | 2025-02-19 | 베렌 테라퓨틱스 피.비.씨. | 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법 |
| CA3263540A1 (en) * | 2022-07-29 | 2024-02-01 | Anavex Life Sciences Corp. | Compositions and methods for the prevention of cognitive decline caused by degenerative diseases |
| US20260124236A1 (en) * | 2022-09-30 | 2026-05-07 | Cyclo Therapeutics, Inc. | Methods for treating early alzheimer’s disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200000840A1 (en) * | 2016-03-20 | 2020-01-02 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4877778A (en) | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| US5569756A (en) | 1995-03-21 | 1996-10-29 | American Maize-Products Company | Purification of chemically modified cyclodextrins |
| US8883494B2 (en) | 2003-11-14 | 2014-11-11 | Adil A. KHAN | In vitro model for neuronal death |
| KR101530050B1 (ko) | 2007-03-02 | 2015-06-22 | 주식회사 노브메타파마 | 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법 |
| WO2013155485A2 (en) | 2012-04-13 | 2013-10-17 | Alessia Fornoni | Method of using cyclodextrin |
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| KR20170012555A (ko) * | 2014-06-12 | 2017-02-02 | 더 유니버시티 오브 노트르 담 듀락 | 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법 |
| WO2016168772A1 (en) | 2015-04-17 | 2016-10-20 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
-
2019
- 2019-10-24 EP EP19805439.7A patent/EP3873604B1/en active Active
- 2019-10-24 JP JP2021547654A patent/JP7446322B2/ja active Active
- 2019-10-24 US US17/289,137 patent/US11925659B2/en active Active
- 2019-10-24 WO PCT/US2019/057784 patent/WO2020092107A1/en not_active Ceased
- 2019-10-24 BR BR112021008139-9A patent/BR112021008139A2/pt unknown
- 2019-10-24 KR KR1020217013055A patent/KR20210084480A/ko not_active Ceased
- 2019-10-24 CA CA3114021A patent/CA3114021C/en active Active
- 2019-10-24 ES ES19805439T patent/ES2992137T3/es active Active
- 2019-10-24 CN CN201980071651.0A patent/CN112996562A/zh active Pending
- 2019-10-24 PT PT198054397T patent/PT3873604T/pt unknown
-
2024
- 2024-01-29 US US18/425,707 patent/US20240415871A1/en not_active Abandoned
-
2025
- 2025-06-09 US US19/232,726 patent/US20250302864A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200000840A1 (en) * | 2016-03-20 | 2020-01-02 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
Non-Patent Citations (1)
| Title |
|---|
| BAI PI NG REN ET AL: "HP-[beta]-cyclodextrin as an inhibitor of amyloid-[beta] aggregation and toxicity", PHYS I CAL CHEMISTRY CHEM I CAL PHYS I CS, vol. 18, no. 20, 1 January 2016 (2016-01-01), pages 20476 - 20485 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025214478A1 (zh) * | 2024-04-12 | 2025-10-16 | 北京华昊中天生物医药股份有限公司 | 一种优替德隆药物组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2992137T3 (es) | 2024-12-09 |
| US20240415871A1 (en) | 2024-12-19 |
| EP3873604A1 (en) | 2021-09-08 |
| US11925659B2 (en) | 2024-03-12 |
| BR112021008139A2 (pt) | 2021-08-03 |
| JP7446322B2 (ja) | 2024-03-08 |
| CA3114021A1 (en) | 2021-05-07 |
| JP2022509358A (ja) | 2022-01-20 |
| EP3873604B1 (en) | 2024-08-21 |
| WO2020092107A1 (en) | 2020-05-07 |
| PT3873604T (pt) | 2024-10-22 |
| CA3114021C (en) | 2025-05-27 |
| US20220008453A1 (en) | 2022-01-13 |
| KR20210084480A (ko) | 2021-07-07 |
| US20250302864A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7446322B2 (ja) | アルツハイマー病を治療する方法 | |
| JP2013537545A (ja) | 筋萎縮性側索硬化症(als)の治療に用いるためのジアゾキシド | |
| Rainov et al. | Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? | |
| KR20140019361A (ko) | 유효량의 (3aR)-1,3a,8-트리메틸-1,2,3,3a,8,8a-헥사히드로피롤로〔2,3-b〕인돌-5-일 페닐카바메이트 및 이의 제조방법 | |
| US20240148782A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| US20220062412A1 (en) | Treatment of alzheimer's disease (ad) with an aluminum salt | |
| TW202339763A (zh) | 用於治療多種疾病之組成物及方法 | |
| CN120826223A (zh) | 鲨肌醇与免疫治疗剂组合用于治疗阿尔茨海默氏病 | |
| CN120051284A (zh) | 用于治疗早期阿尔茨海默病的方法 | |
| AU2015254663B2 (en) | Treatment and prevention of Alzheimer's Disease (AD) | |
| HK40059055B (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| HK40059055A (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| CA3268619A1 (en) | Methods for treating early alzheimer's disease | |
| TW202342072A (zh) | 以環糊精治療高三酸甘油脂血症之方法 | |
| WO2025228863A1 (en) | Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative | |
| CN121604971A (zh) | 用于治疗与焦虑症相关的认知障碍的hip/pap蛋白或其衍生物 | |
| JP2023543132A (ja) | シクロデキストリンによるコレステロール結晶塞栓症の予防方法 | |
| HK40008598A (en) | Use of biotin for the treatment of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |